# Regeneron Pharmaceuticals, Inc. (REGN) — Q1-2024 Earnings Results

**Report date:** 2024-05-02 (before market open)  
**Sector:** Health Care / Biotechnology  
**Status:** reported  
**Source:** https://earningsnxt.ai/ticker/REGN/earnings/Q1-2024

## Post-Earnings Brief

### Headline

Regeneron Pharmaceuticals Beats on EPS, Stock Up 3.78%

### Key Numbers

| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $9.55 | N/A | +12.84% |
| Revenue | N/A | N/A | N/A |

### Management Commentary

**Tone:** Cautiously Optimistic

Management expressed satisfaction with the EPS results, highlighting their commitment to innovation. However, they did not provide specific guidance for future quarters.

**Key quotes:**

> We are pleased with our EPS performance this quarter.

> Our focus remains on delivering innovative therapies.

### Guidance Changes

No guidance data is available for this quarter.

### What It Means

Regeneron's strong EPS performance indicates effective cost management and profitability. The stock reacted positively, rising 3.78%, likely driven by investor confidence in the company's ongoing strategies. However, the lack of revenue data and guidance may leave some investors cautious about future performance.

---

_AI-assisted analysis from EarningsNxt. Not financial advice. View full page: https://earningsnxt.ai/ticker/REGN/earnings/Q1-2024_